|
 U.S. green lights for Vistogard and Lumi, for chemotherapy overdoses
and tumors, and the success of PneumRx coils in severe emphysema may
help counter recent disappointment over sales of BTG's varicose vein
treatment Varithena.
BTG Chief Executive Louise Makin said the positive developments
demonstrated the company was delivering on its strategy to become a
world-leading specialist healthcare business.
The success of PneumRx coils removes a key remaining risk to the
launch of the product in the United States, where it will now be
filed for approval in mid-2016.
Although Deutsche Bank analyst Richard Parkes said the benefit
appeared only modest in the PneumRx coils study, as measured by the
main outcome, secondary clinical results were strong.
BTG shares, which have underperformed in recent months on concerns
about sales of Varithena, were 0.8 percent higher at 630 pence by
1110 GMT.
[to top of second column] |
(Reporting by Ben Hirschler; Editing by Louise Heavens and Mark
Potter)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
